GWM
SPRO icon

Geneos Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Geneos Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-590
Closed -$9K – 2967
2021
Q4 		$9K Hold
590
– – ﹤0.01% 2234
2021
Q3 		$10K Hold
590
– – ﹤0.01% 2235
2021
Q2 		$9K Sell
590
-3,611
-86% -$50.5K ﹤0.01% 2245
2021
Q1 		$57K Hold
4,201
– – ﹤0.01% 1557
2020
Q4 		$61K Buy
4,201
+590
+16% +$9.2K ﹤0.01% 1360
2020
Q3 		$34K Hold
3,611
– – ﹤0.01% 1415
2020
Q2 		$47K Hold
3,611
– – ﹤0.01% 1244
2020
Q1 		$28K Buy
+3,611
New +$31.8K ﹤0.01% 1378

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geneos Wealth Management's SPRO Position: Q1 2022 in Review

Geneos Wealth Management sold out of Spero Therapeutics (SPRO) in Q1 2022, closing a stake of 590 shares — an estimated $9K sold.

Geneos Wealth Management first reported a position in SPRO in Q1 2020 and held it in 8 quarters. The position peaked at $61K in Q4 2020. 100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

  • Geneos Wealth Management reported no remaining Spero Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 590 Spero Therapeutics shares in Q1 2022, an estimated $9K.
  • Geneos Wealth Management first reported a position in Spero Therapeutics in Q1 2020 and held it in 8 quarters.
  • Geneos Wealth Management's Spero Therapeutics position peaked at $61K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on Geneos Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.